Abstract: The number of degradable or biodegradable polymers that are aimed or claimed as aimed at therapeutic purposes is rapidly increasing in literature. In most cases, contributions deal primarily with synthesis. However it is the matching of degradation characteristics to application requirements that is important. This contribution, based on personal experience, is aimed at discussing some of the structure-related complications that can be expected when a polymeric therapeutic device degrades in an aqueous medium or in an animal organism. It is shown that dramatic changes can be observed because of selective degradation of some parts leading to the formation of undesired degradation by-products or undesired changes of properties.
Introduction
For the last sixty years, synthetic polymeric materials have grown progressively up to forming one of the most attractive domains in materials science and in the search for replacing or complementing compounds and materials of natural origin. This is true for most of the human activities and, of course, this is also true for surgery and for pharmacology, two therapeutic domains that are aimed at helping an injured or diseased animal organism to heal. It was in the fifties of the twentieth century, i.e., rather soon after synthetic polymers were invented, that industrial compounds like ultra-high-molecular-weight (UHMW) polyethylene, poly(methyl methacrylate), poly-(ethylene terephthalate), etc., developed as organic materials for classical industrial applications, were introduced as polymeric biomaterials, i.e., as compounds of therapeutic interest.
Starting from the case of degradable sutures aimed at replacing collagen-based Catgut ® ones, people realized that, in biomaterial-based therapies, one has to make a distinction between the definitive replacement of an organ or a function and the use of a therapeutic aid for a limited period of time, namely the healing period after which the foreign material or device becomes a waste, i.e., is no more useful and is left as an undesired foreign body. The first category requires long-term performance, ideally for the rest of the patient's life, whereas time-adapted performance followed by degradation and elimination (bioresorption) from the body is preferable for the second one. The reason for preferring a bioresorbable system instead of a biostable one is twofold. First it precludes useless storage as foreign body material. Basically any artificial polymeric device or macromolecule that is to be used as material in contact with a living system for a limited period of time only should be bioassimilated or eliminated after use in order to avoid storage as a waste. This is becoming compulsory in the case of the human body where high-molecular-weight polymeric compounds are entrapped between skin and mucosa and cannot cross cell-made parenteral physiological membranes like the blood-brain barrier or the vascular walls. Second, it renders the normal stresses to the surrounding tissues and thus provides them with better conditions to consolidate and remodel. Indeed a living tissue requires feeling the surrounding physical forces to organise itself correctly on healing. In the absence of forces, abnormal reconstruction occurs, such as osteoporosis because of stress protection caused by metallic plating in osteosynthesis (bone fracture fixation with metallic plates and screws). This is well documented for bone surgery and bone fracture fixation. Further examples can be found in literature in the case of bioresorbable sutures, staples and meshes, many of these systems having reached the stage of clinical and commercial development.
In the field of pharmacology, the same problem is faced when one wants to use polymers to make drug delivery systems that are typical time-limited therapeutic aids. In the past decades, pharmacists, in connection with polymer scientists, have introduced various polymer-based drug delivery systems, namely implants and particulates, macromolecular micelles of amphiphilic diblock or triblock copolymers, macromolecular aggregates of hydrophilic macromolecules bearing hydrophobes as pendent chains, polyelectrolyte complexes, macromolecular prodrugs and, last but not least, hydrogels. Most of these systems were investigated using biostable commercial polymers. However, for all of them, the respect of living organisms imposes the use of bioresorbable polymeric backbones. Generally forgotten in most of the reported investigations, this constraint is to be included into the list of criteria of a given application because of the pressure of regulatory agencies. It is worth to note that sterilisation should be included as well because of its effects on the integrity of polymer chains.
So far, only a small number of polymeric backbones have been identified as able to fulfil the criteria of drug delivery in human. Given the diversity of the previously mentioned systems, homopolymers such as the commercially available poly(glycolic acid) or poly(lactic acid) stereocopolymers (copolymers of enantiomeric lactyl repeating units) cannot allow one to fulfil the particularities of each of them. Therefore, people have looked at copolymerization to enlarge the range of structures capable of providing the desired specific properties of each type of devices. If the number of contributions dealing with the synthesis of degradable or biodegradable polymers presented as aimed at therapeutic applications is rapidly increasing these days, only little attention is generally paid to the degradation mechanisms. However, these mechanisms are critical insofar as the loss and the rate of loss of initial properties are concerned because they condition the structure of polymer chains. They are critical also for the late stages of chain cleavage and generation of degradation byproducts. Indeed, in the case of in vivo tissue reconstructions, one of the major criteria, beside biocompatibility-related ones, is a rate of degradation compatible with the rate of tissue consolidation and tissue remodelling. If degradation is too slow, the degradable device will be seen as biostable and encapsulated by fibrous tissue for a rather long period of time in soft or hard tissue reconstruction. If it is too fast, it will not be helpful as temporary support or will be exhausted too rapidly in the case of sustained drug delivery. If size exclusion chromatography, SEC, is a recommended technique to monitor the early stages of degradation of a polymeric chain and of the decrease of molecular weight, high performance liquid chromatography (HPLC) is an excellent tool to monitor the late stages when soluble oligomers and the end product appear. Capillary zone electrophoresis, CZE, is also a technique of interest provided the oligomers and the end product are electrostatically charged [1] .
This contribution looks at some of the problems that people face when they deal with degradable polymeric devices aimed at temporary therapeutic applications. It is impossible to comment on all the degradable polymers and copolymers or other polymeric systems that are in literature, mostly because discussions are generally focussed on synthesis and on structure-properties relationships [2] [3] [4] [5] and not on structure-related complications of degradation characteristics as intended here. Therefore, the following will be primarily based on our thirty-year experience, with special attention being paid to some aspects related to enzymatic degradation and to the degradation of some stereocopolymers and copolymers. A secondary aim is that the selected examples taken in the family of aliphatic polyesters be of interest to those who are not yet familiar with the field because many of the underlined phenomena are applicable to other types of degradable polymers.
Remarks on polymer degradation
To achieve degradation of biopolymers, namely proteins or polysaccharides or polynucleotides, Mother Nature has elaborated remarkable selective processes. Indeed, these polymers had to be chemically stable under the conditions ensuring life and degradable when necessary. With these regards, the choice of the complex enzymatic and cell machineries is remarkable and allows an efficient and controlled turnover of living systems. However, in the world of degradable polymers, one must have in mind that enzymes can be present in nature only if living cells are present and that bioactive enzymes can be present only if the right cells are present. These requisites are not always taken into account by polymer chemists or pharmacists in their search for natural or artificial polymers and polymeric matters that can serve as material and that can be assimilated or eliminated from an animal body via natural pathways when becoming waste. The fact that poly(glycolic acid), PGA, does not require an enzyme to be degraded in the human body was one of the reasons for it to be the first artificial degradable polymer developed as suturing material in the early sixties [6] . Since then, several other polymers and many copolymers have been introduced either as enzymatically or as chemically degradable in an animal body. Among them, only very few have reached the stage of commercial exploitation, mainly because of difficulties to have all the criteria to be respected under control.
Actually, literature is sometime confusing regarding enzymatic degradation and cellmediated biodegradation. If cell-mediated enzymatic degradation definitely involves enzymes and enzymatic degradation and is thus relevant to the term 'biodegradation', enzymatic degradation observed at the lab stage should not be considered as biodegradation. Indeed, isolated enzymes can be found that are active against a given artificial polymer and that will never be under conditions where they can be active in nature. An excellent example is the degradation of poly(lactic acid) by proteinase K, an enzyme issued from pathogenic bacteria, that is neither available outdoors nor in an animal body. Other good examples are those of poly(ε-caprolactone), PCL, and poly(β-hydroxybutyrate) that are rapidly degraded in vitro by lipases and by PHB depolymerase, respectively, but are not biodegradable in an animal body where such enzymes are not present or active.
Of course, as most of the aliphatic polyesters, PCL and PHB can degrade hydrolytically in the human body or in contact with cells or tissues. However, their degradation rates are much too slow to allow matching degradation rate to tissue growth rate, or more generally to specifications required for surgery, drug delivery and scaffolding in tissue engineering. This remark is particularly of interest in the case of tissue engineering where a degradable or biodegradable scaffold has to allow the growth of cells with the right phenotype to form a tissue that can be implanted and also to degrade under such conditions that the polymer is ideally eliminated while vascularisation and grafting occur and not long after. Adjusting the degradation rate to tissue reconstruction has been successful in wound suturing and bone reconstruction only when an artificial degradable polymeric device is implanted directly in vivo. Good examples can be found in the case of lactic acid-based interference screws used in knee anterior cruciate ligament reconstruction using autografts [7] [8] . So far, no construct composed of a degradable scaffold and cultured tissue is commercially exploited. One of the potential applications is the implantation of degradable constructs where fibroblasts and keratinocytes are grown as dermis and epidermis. Recently, we have found that the growth of keratinocytes was dramatically affected when the support generated glycolic acid because of the desired degradation during cell growth. This led us to select glycolic free the poly(DL-lactic acid) stereocopolymer as support instead of any of the poly(glycolic acid-co-lactic acid) copolymers [9] .
Degradation of stereocopolymers and copolymers
In the field of biomedical prostheses, one of the main problems is the response of body tissues to the presence of foreign body materials, especially to small particles that can generate dramatic inflammatory responses as those observed in the case of implants in contact with bony tissues. With this regard crystallites present in semicrystalline degradable polymers are particularly dangerous, especially when they are liberated as tiny particles during degradation, because degradation proceeds generally faster in amorphous domains than in crystalline ones.
One potential solution is to consider totally amorphous degradable polymers starting from the idea that being amorphous, they will not generate crystalline residues. This is the case when polymer chains are highly disordered. However, starting from an initially amorphous degradable polymeric device does not prevent from the formation of crystalline residues.
Formation of crystalline residues can be observed when a device made of stereoregular degradable polymer chains is made amorphous by quenching as it is often the case in injection moulding. Indeed, crystallisation can occur at body temperature because of chain relaxation, a phenomenon facilitated by the absorbed water that acts as a plasticizer. Slow crystallisation due to relaxation is a general phenomenon that is not specific to degradable polymers. However, there are other cases that are more subtle.
Poly(L-lactic acid-co-D-lactic acid)s
Using the chirality of lactic acid molecules to make poly(lactic acid)s of different stereoregularity is one of the available means to modify macroscopic characteristics such as physical, thermal and mechanical properties, degradation rate and, to a lesser extent, the solid-state glass transition temperature, taking the homopoly(Llactic or D-lactic acid)s as reference [10] [11] . This means has been exploited for various applications. However, it is now known that all the ester bonds forming stereocopolymer chains are not equivalent, a feature that was suspected many years ago [12] . Actually, the cleavage of ester bonds engaged in various diads, triads, tetrads, etc. of L-and D-chiral units that can be found in a poly(L-lactic acid-co-Dlactic acid) chain is stereodependent. Although the differences are very difficult to quantify, qualitatively one observes that ester bonds that are part of disordered stereosequences degrade faster than poly(L) or poly(D) isotactic ones. The result is a change in chiral unit compositions with a trend to increase the stereoregularity of the chain at the last stages of the degradation process. The effect is thus very much dependent on the composition of the feed in L-and D-lactic acid or lactide and on the chiral repeating unit distribution that conditions the distribution in stereosequences. The effect is also very much dependent on the polymerisation mechanism that is well known to determine the repeating unit distribution. For example, for similar molecular weight and molecular weight distributions, racemic poly(lactic acid)s made by lactic acid step growth polymerisation, by lactide ring opening polymerisation and by lactide stereoelective or stereoselective ring opening polymerisations will not exhibit the same repeating unit distributions and thus generate the same amounts and the same types of crystalline residues. The differences are schematically represented Fig. 1 .
As crystalline residues are not recommended in an animal organism, it is not always the best stereocopolymer in terms of material properties that will be the recommended compound for biomedical applications. It is obvious that similar chiralityrelated selectivity in stereocopolymers is likely to occur in other degradable polymers composed of chiral repeating units.
Poly(D-lactic acid-co-L-lactic acid-co-glycolic acid) copolymers
A similar situation has been found in copolymers and in chiral copolymers. Here again, a huge number of different repeating unit distributions can be found in such polymer chains in terms of short n-ads. It is now well known that in a poly(L-lactic acid-co-glycolic acid), PLAGA, degradation is faster in n-ads composed of glycolyl units that in n-ads composed of lactyl units, the fastest rate being apparently observed for n-ads composed of lactyl and glycolyl units. Once again, the presence of n-ad-dependent degradation rates will lead to composition changes (Fig. 2) , a trend that will be accentuated if one of the monomers is more reactive than the other as it is the case in lactide-glycolide ring opening copolymerisation [13] .
Glycolide is known to be more reactive than lactide, and thus poly(glycolic acid) sequences will be formed preferentially at the beginning of the copolymerisation reaction. In other words, all the copolymer chains will not have the same repeating unit distributions because of the dependence of this parameter on the advance of the reaction. The situation can be more complex when one deals with PLAGA involving both chiral lactyl units. Here again, similar features are to be expected in the case of other hydrolytically degradable polymers. We have reported examples for poly(β-malic acid-co-β-benzyl malate) copolymers (Fig. 3) . LGLLGLGGLGLGLLGLGGLGLLLGLGGLGGLGGLGLLGGL -no blocky fragment -no crystalline residue -short blocky segments -crystalline residues made of short crystallisable segments
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PLAGA copolymers made by polycondensation of lactic acid and glycolic acids : almost random distribution PLAGA made by ring opening polymerisation of 50/50 dimeric lactide and glycolide : non random distribution of units because of pair addition and preferential polymerisation of glycolide at the beginning Fig. 2 . Formation and morphology of the residues formed at the last stages of hydrolytic degradation of poly(lactic acid-co-glycolic acid) copolymers and stereocopolymers of different initial distributions in repeating units
In such copolymer chains, the hydrophilic and acid poly(β-malic acid) sequences degrade much faster than the hydrophobic poly(β-benzyl malate) ones, even for compositions providing water solubility [14] . For some compositions that are at the limit of solubility, copolymers can form core-shell nanoparticles spontaneously, which are stabilised by a corona of poly(β-malic acid) segments located at the surface. Because the stabilising segments degrade faster than those forming the core, such highly dispersed nanophase is rapidly destabilised and bigger aggregates are formed that can go up to macroscopic precipitation. It is obvious that such undesired evolution of the particles can be dramatic for a therapeutic application like micelle-based drug delivery, because of a change of drug release rate and also because of recognition as foreign body particulates by macrophages. 
Labelling to monitor the fate of degradation by-products
Thanks to simple organic chemistry applied to aliphatic polyesters, two types of labelling were exploited to monitor the fate of PCL and of racemic PLA 50 (50% L-/ 50% D-lactyl units obtained by ring opening polymerisation using zinc lactate as the initiator) under conditions mimicking physiological conditions, namely pH 7.4, 37°C and 0.15 M NaCl. On the one hand, PCL and PLA 50 were radiolabelled by partial tritiation in α-position with regard to the carbonyl groups using a process based on the formation of carbanionic sites by reaction with lithium diisopropylamide, LDA, at low temperature [15] and reaction with tritiated water as electrophile [16] . On the other hand, PCL and PLA 50 were labelled by covalent binding of a fluorescent dye on a very small number of repeating units using the same method of activation and naphthoyl chloride as the electrophile. The four labelled aliphatic polyesters were allowed to degrade hydrolytically over a period of 200 days. As expected there was no release and thus no formation of soluble degradation by-products during this period in the case of PCL regardless of the labelling method. In contrast, PLA 50 did degrade according to the release of radioactive and fluorescent soluble compounds in the ageing media. However, the two labelling methods did not lead to the same results [17] . Degradation was faster according to radioactivity measurements than according to fluorescence (Fig. 4) . The discrepancy can be easily explained by the fact that tritiated lactyl units were absolutely equivalent to the cold lactyl units whereas the segments including lactyl units that bear the fluorescent moieties were much less soluble in the aqueous medium than segments of similar length free of dye. The difference of solubility was thus responsible for the apparently slower degradation. The change in solubility of released degradation by-products described here can be easily extended to polymer therapeutics composed of a degradable polymeric carrier to which drug molecules are attached if one considers the dye as a drug model. Another example of deviated composition because of selective degradation along a polymer chain was found in the case of copolymers composed of hydrophobic aliphatic polyester blocks bound to hydrophilic poly(ethylene oxide) blocks that are able to form highly swollen physically cross-linked hydrogels when the ratio EO/LA is in a convenient range [18] . Because of the hydrolytic degradation of the PLA segments, the hydrophobic blocks attached to the stable PEO decrease in length. Sooner or later, the formed PEO-bearing small residual PLA segments become soluble whereas the PEO-free PLA segments are more and more hydrophobic, the average LA/EO ratio of the insoluble residual material increasing with time [19] . Again, such behaviour is predictable for comparable hydrolysable blocky copolymers.
Conclusion
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In this contribution we have tried to show that attention must be paid to the degradation characteristics up to the very end when one wants to take advantage of degradable polymers for therapeutic purposes. The literature is rich insofar as synthesis of degradable or potentially degradable polymers is concerned. However, in most cases little is said or known about the degradation characteristics and the fate of degradation by-products from both the chemical control and the biocompatibility points of view. Actually the polymer specialist, the surgeon and/or the pharmacist acting separately, or almost separately, cannot cover the whole range of problems and phenomena that are found when a degradable polymeric system is in contact with living cells, tissues and organisms. Only a concerted multidisciplinary approach can provide a vision large enough to attain success at the level of therapeutic application in human. It is with such a multidisciplinary approach that we contributed to the development of PLA-based bioresorbable devices for bone surgery in France in 1990 after more than fifteen years of research and development. Nowadays, targets like polymeric drugs and prodrugs, bioresorbable stents, and tissue engineering followed by implantation and vascularisation are relevant to a similar strategy but it is difficult to set up and to handle.
